Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07716865 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety, Tolerability and Efficacy of NPI-001 in Patients With Hereditary Cystatin C Amyloid Angiopathy (HCCAA)

Study acronym: HCCAA
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
Arctic Therapeutics
3 trials monitored
See all monitored trials
Dementia
1,978 trials monitored
See 106 trials at risk
Amyloidosis
330 trials monitored
See 20 trials at risk
The study aims to measure safety, tolerability and biomarker-based efficacy of NPI-001 (AT-001) in Subjects with Hereditary Cystatin C Amyloid Angiopathy (HCCAA). In the study participants receive increasing dose or active treatment (250 mg vs 500mg vs 750 mg) or matched placebo in the form of tablets BID.
Trial Details
NCT Number NCT07716865
Lead Sponsor Arctic Therapeutics
Conditions
(from sponsor)		 Hereditary Cystatin C Amyloid Angiopathy (HCCAA), Hemorrhage Brain, Hemorrhage Cerebral
Related terms Cerebral Amyloid Angiopathy, Familial, Cerebral Hemorrhage, Dementia, Intracranial Hemorrhages
Enrollment 15 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov